Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer.

摘要: OBJECTIVES To test the hypotheses that African American patients and older with stage IV colorectal cancer were less likely to receive newer chemotherapy agents. STUDY DESIGN Retrospective cohort design. METHODS Among 5068 Surveillance, Epidemiology, End Results-Medicare diagnosed as having between 2000 2002, a total of 2466 received included in analysis. Irinotecan hydrochloride was first "newer" agents marketed first-line add-on agent. Descriptive statistics generated, multivariable logistic regression run estimate odds receiving irinotecan among within 2 months initiation. RESULTS had lower initiating treatment than white (adjusted ratio, 0.641; 95% confidence interval, 0.453-0.907). An age disparity also found, all groups being significantly initiate youngest group: adjusted (relative aged 66-70 years) significant 71 75, 76 80, 80 years (odds ratios, 0.708, 0.527, 0.213, respectively). CONCLUSIONS Disparities selection exist for cancer. On chemotherapy,